FBXW22 Inhibitors
FBXW22 inhibitors are chemical compounds that specifically target and inhibit the function of the FBXW22 protein, which is part of the F-box family of proteins. FBXW22, like other members of this family, is involved in the ubiquitin-proteasome system, which regulates protein degradation. F-box proteins serve as substrate recognition components in Skp1-Cullin-F-box (SCF) E3 ubiquitin ligase complexes. These complexes are responsible for ubiquitinating specific protein substrates, marking them for degradation by the proteasome. By inhibiting FBXW22, these compounds interfere with the recognition and ubiquitination of substrates that are normally regulated by the FBXW22-containing SCF complex.
The inhibition of FBXW22 disrupts cellular processes dependent on the controlled degradation of target proteins. Such processes can include cell cycle regulation, signal transduction, and protein homeostasis, as they rely on the timely removal of certain regulatory proteins. FBXW22 inhibitors are often developed with the intent to study the specific roles of the FBXW22 protein in these cellular pathways. Their chemical structure typically involves elements that enable specific binding to FBXW22, preventing its interaction with its protein partners or substrates within the SCF complex. By doing so, researchers can gain insights into the molecular mechanisms underlying FBXW22 function, the substrates it regulates, and its role in maintaining cellular homeostasis. These compounds provide valuable tools for understanding protein degradation pathways and their impact on various cellular activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a direct inhibitor, disrupts Fbxw22 by inducing DNA cross-linking. This leads to activation of DNA damage response pathways, culminating in the stabilization and inhibition of Fbxw22. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Acting as an indirect inhibitor, Y-27632 targets Fbxw22 through the Rho/ROCK signaling pathway. It inhibits ROCK, affecting actin cytoskeleton dynamics and downstream modulation of Fbxw22 expression. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib, a direct inhibitor, disrupts Fbxw22 by inhibiting poly(ADP-ribose) polymerase (PARP). This induces DNA damage, activating cellular repair mechanisms and leading to the stabilization of Fbxw22. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Acting as an indirect inhibitor, 5-Fluorouracil targets Fbxw22 through the thymidylate synthase pathway. By inhibiting thymidylate synthase, it disrupts DNA synthesis, influencing downstream modulation of Fbxw22. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII serves as an indirect inhibitor, affecting Fbxw22 through the JNK signaling pathway. It inhibits JNK activity, impacting the phosphorylation of specific transcription factors and modulating Fbxw22 expression. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 serves as an indirect inhibitor, influencing Fbxw22 through the CaMKII pathway. By inhibiting CaMKII, it disrupts calcium signaling, leading to downstream modulation of Fbxw22 expression and function. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
UCN-01, a direct inhibitor, disrupts Fbxw22 by inhibiting the CHK1 kinase. This prevents CHK1-mediated DNA damage response, leading to the stabilization and inhibition of Fbxw22. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e acts as an indirect inhibitor, targeting Fbxw22 through the Bcr-Abl pathway. By inhibiting Bcr-Abl, it influences cell proliferation and downstream modulation of Fbxw22 expression in certain cellular contexts. | ||||||